Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of inhaled Ad5-vectored XBB.1.5 COVID-19 booster vaccine in previously vaccinated adults
ChiCTR2300075626Phase 3Recruiting
- Sponsor
- Seventh Medical Center of the People's Liberation Army General Hospital
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant novel coronavirus XBB.1.5 variant vaccine in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Seventh Medical Center of the People's Liberation Army General Hospital. Primary endpoint: Incidence of adverse reactions. Started Sep 2023; status: recruiting.
02
Drugs
recombinant novel coronavirus XBB.1.5 variant vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300075626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075626.